INSTITUTE OF INTELLECTUAL PROPERTY RESEARCH & DEVELOPMENT

With Support of
SUGHRUE MION, PLLC, USA
&
DR. SCHÖN & PARTNERS, EUROPE
&
MARIETTI GISLON E TRUPIANO S.r.l. (EUROPE)
&
KHURANA & KHURANA, IP ATTORNEYS, India

Presents
Three- Days International Symposium

For
IP Group & R&D Scientist, Patent Agent & Attorneys at Pharmaceutical, Biotech & Chemical Industry

With Focus On:
Management of Patent Portfolio
Pharmaceutical, Biotech & Chemical Industry
The Best Way Forward

26th – 28th September 2013, at Hotel Hilton, (Andheri East) Mumbai

www.iprd.com  www.khuranaandkhurana.com
SCHEDULE

<table>
<thead>
<tr>
<th>Dates:</th>
<th>26-28th September 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venue:</td>
<td>Hotel Hilton (Andheri East) Mumbai</td>
</tr>
<tr>
<td>Registration Fees:</td>
<td>Rs. 12000/- Per delegate (If 3 or more delegates are nominated by any company the delegate fees will be Rs. 10000/- Per delegate)</td>
</tr>
<tr>
<td></td>
<td>For Foreign Delegates: USD 300/- Per Delegate</td>
</tr>
</tbody>
</table>

Please Forward the Delegate Fees with the following details:
Name, Organization, Designation, Address and Contact Details along with the cheque drawn in favour of "M/S IIPRD”

Mr. Tarun Khurana
Institute of Intellectual Property Research & Development
IFAIA Centre, S/19-22, Greater Noida Shopping Plaza, UPSIDC Site-IV, Kasna Road, Opp Radisson Blu Hotel, Greater Noida-201308, UP, India.

OR

Delegate Fees be transferred to:
M/S IIPRD
Bank Name: UCO Bank
Branch Name: Greater Noida
Bank Account Number: 19620210002476
Bank Address: G.N. Shopping Plaza, Plot No- S-7/1, Site-IV, Kasna Road, Greater Noida
MICR Code: 110028055
IFSC Code: UCBA 0001962

For any query contact:
(i) Ms. Meenakshi Khurana, (M)91-9910307992, E-mail:- meenakshi@iiprd.com
(ii) Mr. Tarun Khurana, (M) 9810617992, 9810281321
E-mail:- Tarun@iiprd.com, iiprd@iiprd.com.
Ph : +91-120-2342010, Fax: +91-120-2342011

ABOUT THE WORKSHOP

With Patents becoming a core part of existing economic ecosystem, particularly for Pharmaceutical, Biotech, Chemical & Drug Industry, exploitation of Patent Portfolio has become an industry in itself; especially with the cost of development and protection of the portfolio being enormous. It is therefore crucial to understand important Patent issues, not only for IP team but even more importantly for R&D Scientist so as to minimize the efforts in Patent Development and to maximize the commercial gains. It is therefore important for Corporate and concerned stakeholders to understand the nitty-gritty’s of patent portfolio creation, protection, management, and commercialization, without which there would always remain an open door for a serious blow either from an infringement perspective or from a patent invalidation perspective or the portfolio would remain under commercialized. This is precisely why the number of major patent litigations are growing between competitors and contemporaries, besides the growing threat from international exploiters.

This Symposium features presentation of all important patent issues, as mentioned in this brochure. The speakers are a unique gathering of Patent Attorneys, Litigators and Legal Counsels, who have extensive years of experience in their professional fields. These Speakers will put across to the delegates the real insight of Patent Laws, Practices and Commercial perspectives as prevalent and practiced in United States and Europe. The Programme will provide an opportunity to receive first-hand information including recent Judgment on various issues from the experts in the fields.

WHO SHOULD ATTEND

PROGRAMME

DAY-1

Registration : 0900 hrs onwards

0915-1015: Implications of the Supreme Court Decision in Myriad: What does the decision mean for the life-sciences industry? Which live gene patents will be opposed in post-grant opposition proceedings at the USPTO? How will this decision impact protein patents claiming isolated polypeptide sequences covering human proteins?

1015-1200: When is a patent held invalid on a ground of lack of enablement? What constitutes undue experimentation in practicing the full scope of compound and method claims when only limited information is available in the specification (Wyeth v. Abbott Laboratories (Fed. Cir. 2013); Boston Scientific v. Wyeth); Interplay between infringement and full scope enablement; How is the adequacy of written description and enablement determined for pharma and biotech patents? What are best practices for complying with the disclosure requirements of 112?

1200-1300: Lunch

1400-1530: Update on test for obviousness: Impact of American Invents Act (AIA) on section 103 of the US patent act; Post-AIA treatment of KSR and Patent Validity Requirements; What practices should be employed in order to meet the non-obviousness requirement? Recent Nonobviousness Developments; impact of new obvious considerations in the courts and USPTO;

1545-1645: Strategies for effective patent drafting for the best protection in the US market; analyzing invention disclosure and capturing them in a sophisticated set of patent claims comparing the different approaches of EPO and USPTO; How patent drafting can influence the development and the outcome of subsequent patent litigation.

DAY-2 [US Scenario-ANDA]

0915-1015: Overcoming the challenges to establishing biosimilarity; Biosimilars litigation strategies in light of validity assessment post-AIA; Lessons learned so far from global biosimilars development and litigation; The use of citizen’s petitions in the biosimilars context; Claim drafting and patent prosecution issues for biosimilars and innovators;

1015-1115: Substantive Legal issues in ANDA Litigation for different type of Claims including compound and composition claims, method of treatment claims, formulation claims, and claims directed to methods for causing biological effects; Strategies for litigating claims of direct and indirect infringement in view of Akamai v. Limelight; Reassessing inducement and divided infringement in the context of Orange Book-listed method patents;

1130-1215: The use of AIA in pharma patents; a look at the first year in review.

1215-1300: (Azy Kokabi): Settlement of Paragraph IV lawsuits; Supreme Court ruling in FTC v. Actavis: involving "reverse payment" settlement agreements between branded and generic drug companies;

1300-1400: Lunch
1400-1530: Update and Trends on Recent Paragraph IV disputes and litigation: Federal Court, PTO proceedings & ITC actions; Implications on Patent Prosecution and Litigation Strategies; which strategies have been successful?

1545-1745: Mock examination of expert witness in crystalline form patent litigation, followed by closing arguments.

1800-1845: Open House to answer any question the delegates may have on any Patent Issue

DAY-3 [EP Scenario]

0930-1115: Unitary patent and Unified Patent Court: Introduction and latest developments; Strategies in light of the latest developments and how in- house counsels are altering their business strategy accordingly; understanding the standards for patentability, filing requirements, claim construction, and obviousness or inventive step in EU.

1130-1315: Comparing and contrasting the opposition procedures at the EPO and US post-America Invents Act; Third Party Observations; Oral proceedings at the EPO; Recent trends in pharmaceutical and biotechnology patent law and practice in the European Patent Office; how to effectively understand and respond to communications from EPO examiners for avoiding prosecution pitfalls; Enforcing your EP patent; Judicial systems; The doctrine of equivalence – recent developments in European case law

1315-1415: Lunch

1415-1530: Understanding enforceability of patents; an overview of the infringement proceedings, evidence and preliminary injunctions; unitary patent and European patent litigation; Patent Office insights on key challenges in patent lifecycle and SPC regulation; Recent Decisions in SPC matters; Data Exclusivity

1540 to 1720: Claim Drafting – Practical Approach: claim structure, categories, language and impact on proceedings at the EPO; Evaluation of Filing Routes in Europe and Cost Effectiveness: European IP landscape, national peculiarities (e.g. Germany, Italy, France), evaluation of various routes in view of cost/time distribution; and Future Development of the European Patent System

1720-1730: Answering any question the delegates may have on European Scenario

ABOUT THE FACULTY

Mr. Chid Iyer: Chid received a B. Tech in Chemical Engineering from IIT, Bombay in 1984, MS in Chemical Engineering from University of Akron and MS in Computer Science from the University of Tennessee Space Institute. He received his JD from Georgetown University in 1997. Chid is a partner of International Law Firm of Sughrue Mion and is involved in all aspects of patent practice including litigation, prosecution and client counselling in a variety of technologies with focus on chemical and pharmaceutical. Chid has prepared and prosecuted over 100 applications for a leading research laboratory.

Dr. Christoph Schön: Dr. Schön is a Founding Partner at a Patent Law Firm Dr. Schön & Partners, based in Munich, Germany. As a patent attorney with many years of practical experience, he has pursued numerous patent applications and advised clients on patent disputes in many areas including basic inorganic and organic chemistry research, pharmacy, steelmaking, bioengineering, and polymer chemistry. In seminars and lectures, he has shared his broad knowledge of German and European intellectual property rights and the rights of other jurisdictions with attendees from around the world. Dr. Schön is licensed to practice before the German Patent and Trademark Office (GPTO), the German Patent Court, the European Patent Office (EPO), the Office for Harmonization in the Internal Market (OHIM), the World Intellectual Property Organization (WIPO), and — in patent nullity cases — the German Supreme Court.
Mr. Michael R. Dzwonczyk: Michael is a partner at Sughrue Mion and has about 20 years of experience in successfully representing multinational companies in patent litigation, including trials and appeals of patent cases. His experience has encompassed technical areas that include pharmaceuticals, recombinantly produced hormones, protein synthesis and expression products, fibers, and medical devices. Michael also counsels clients on intellectual property issues, including validity and infringement of intellectual property rights, licensing and contract matters and Hatch-Waxman issues.

Renita S. Rathinam: Rathinam did her B.S. Biology, with honors in the year 2000 from Emory University, M.S. Biochemistry and Molecular Biology with honors, 2004 from Georgetown University and J.D. from University of North Carolina School of Law. Rathinam practises in District of Columbia and at U.S. Patent and Trademark Office. Rathinam has served as litigation counsel in matters involving the chemical, pharmaceutical and mechanical arts and has significant experience in nearly all pre-trial, trial, and post-trial aspects of patent litigation. Central to Ms. Rathinam’s practice is Hatch-Waxman Act analysis, and as such she has represented a number of pharmaceutical companies in ANDA/NDA related actions. She also engages in pharmaceutical/biotechnology patent infringement and validity opinion practice.

Dr. William Simmons: Simmons is an associate at Sughrue Mion and works out of the Washington office. He did his masters in Biological Sciences in 1995. Simmons practice focuses on worldwide procurement, defense and enforcement of patents in the biotechnology and chemical industries. Simmons works in all areas of patent law, including interferences, reexaminations, oppositions and prosecution. Simmons prepares opinions regarding patentability and infringement and conducts freedom-to-operate analysis. He did his Post-doctoral Fellow from National Institute of Health at New York University.

Ms. Azy S. Kokabi: Azy S. Kokabi practice focuses on worldwide procurement, defense and enforcement of patents in the biotechnology and pharmaceutical industries, with focus on prosecution, interference, and litigation motions practice. Kokabi did her post graduation in Biology and JD from George Mason University School of Law. Kokabi has served as counsel in interference proceedings and related matters, before the Board of Patent Appeals and Interferences and the Court of Appeals for the Federal Circuit. Kokabi counsels clients about preinterference matters, such as provoking or avoiding interference proceedings, copying claims, and evaluating inventorship disputes. Prior to joining Sughrue Mion, Ms. Kokabi also served at the U.S. Patent and Trademark Office as an Examiner.

Gabriele Gislon: Gabriele Gislon holds a master’s degree in Chemistry from the University of Milano, a post-graduate diploma in European Patent Litigation from the University of Strasbourg (France) and a post-graduate certificate in Engineering from the Engineering School of Milan and began his career in IP in 1986. He is a qualified Chartered Chemist, Chartered Italian Patent and Trademark Agent and a European Patent Attorney. Founding and Managing partner of MGT - Marietti, Gislon e Trupiano. He is an appointed member of the EPO Examination Committee for the European Qualifying Examination (EQE-ECIII). He is a speaker for the University of Strasbourg course in European Patent Litigation. As a patent attorney he is involved in chemical, biotech and chemical-related fields with focus on drug synthesis; natural products extracts; and nanochemistry. As a patent litigator he practices before the EPO; in Italy he is also a Court Technical Expert for the Patent Court of Milano. Recent cases include nebivolol, fluvastatin, finasteride and UHMWPE fibers.
ABOUT THE ORGANISER

IIPRD:
IIPRD is a premier IP Consulting and Licensing Firm with a diversified business practice providing services in the domain of Commercialization, Valuation, Licensing, Transfer of Technology and Due-Diligence of Intellectual Property Assets along with providing complete IP and Patent Analytics and Litigation Support Services to Indian and International Corporates. IIPRD has been established precisely to assist the business houses in strategizing their growth by leveraging their IPR’s through effective Creation, Promotion, Protection, and Commercialization of IP. IIPRD has a legacy of over twelve years of existence and is among the first Indian IP Firms to have core focus on Commercialization, Technology Transfer, and Licensing for numerous Indian and Global Corporates.

SUGHRUE MION:
Sughrue Mion is one of the world’s leading intellectual property law firms managing traditional and non-traditional intellectual property rights, for about five decades, with a wide range of clients around the world. Sughrue’s more than 100 lawyers protect ideas - all ideas - and for the last 50 years have been helping their clients to develop, obtain, protect and leverage their intellectual property rights in technology areas ranging from a submicroscopic sequence of DNA to a vast constellation of satellites circling the globe. Sughrue’s Pharmaceuticals, Biotechnology, Chemical attorneys are trained in technical disciplines that include molecular and cellular biology, biophysics, pharmaceuticals, chemistry, immunology, virology, genetics and agriculture biotechnology. Their experts are particularly well versed in drafting claims to ensure the broadest possible coverage and have a long established expertise in handling patent interference proceedings that may be critical to determining basic patent rights in new areas of biotechnological and pharmaceutical industries. Sughrue Mion handles a wide range of IP litigation matters for clients around the world.

DR. SCHÖN & PARTNERS:
Dr. Schön & Partners is an international intellectual property law firm with many years of loyal client relationships for start-up, mid-sized and large industrial clients, providing full range of services necessary for comprehensive support in the areas of industrial and intellectual property and copyright law. Dr. Schön & Partners assist their clients in obtaining patent protection for commercially valuable inventions, in leveraging their investment in technological research and development, and in driving their rapid expansion into any global market they wish. Dr. Schön & Partners has many years of practical experience and in-depth knowledge of the law which forms the basis for the advisory expertise.

KHURANA & KHURANA ADVOCATES & IP ATTORNEYS:
Khurana & Khurana Advocates and IP Attorneys is more than a full service IP Law firm. K&K was formed in the year 2006 with the very focus of providing End-to-End IP Legal Services along with its Sister Concern "Institute of Intellectual Property Research and Development (IIPRD)", which supplement each other in order to provide end-to-end services to the corporate world in the IP Field. K&K and IIPRD together form a niche in the IP domain by taking any corporate from the stage of IP Creation and Protection through its team of Attorneys to the stage of IP Valuation, Licensing, and Commercialization. K&K through its young and qualified team of Attorneys/ Practitioners giving a rare synergy of legal opinion, out-of-box thinking for protection of ideas/IP's and entrepreneurial spirits to its client base.

MARIETTI, GISLON E TRUPIANO
Marietti, Gislon e Trupiano is an IP firm dealing with all the activities and procedures related to obtaining and protecting industrial property rights. The company is the result of the merger, in 2001, of two companies "Marietti and Gislon" and "BREVETTI EUROPA S.r.l.", active in the same field since mid-70's and the beginning of 80's. In Italy, the firm's main office is in Milan with subsidiary offices in Lecco, Novara and Perugia; the firm is also active in Spain through sister company Torner, Juncosa i Associats in Barcelona. The office in Munich is mainly used for preparing Oral Proceedings. Marietti, Gislon e Trupiano directly provides, through its registered attorneys, a complete range of IP services including the filing and the prosecution of patent applications before the Italian Patent and Trademark Office (UIBM), the European Patent Office (EPO), and the International Patent and Trademark Office (WIPO).